GT Biopharma IncGTBP
Price$6.20

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$30.4MTTM through 31 Mar 2026
Free Cash Flow -$13.2MTTM through 31 Mar 2026

Margins

Current

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.14x
Net Debt-$8.9Mnet cash position
Cash & Equivalents$8.9M

Quality Metrics

Earnings-Beat Rate25.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
GT Biopharma, Inc.$0
View details

The company operates as a single reportable segment focused on the development of its TriKE platform.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.